Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- MHLW Proposes Introduction of Administrative Fines for Improperly Earned Revenues
November 27, 2018
- MHLW Panel Recommends Conditional Approval for Nipro’s Stem Cell Product for Spinal Cord Injury
November 26, 2018
- MHLW Eyes Drastic Change to Cost Effective Analysis Flow, Enhanced Discussions Upfront
November 22, 2018
- MHLW Proposes Quarterly Product Selections, Price Tweaks for CEA Scheme: Chuikyo
November 22, 2018
- MOF Panel Urges Govt to Use Economic Evaluations for Reimbursement Decisions: FY2019 Budget Recommendation
November 21, 2018
- Amgen Astellas’s Osteoporosis Med Romosozumab Up for MHLW Panel Review on Dec. 3
November 20, 2018
- Keytruda’s MSI-H Cancer Use Up for MHLW Panel Review Nov. 29; Wider Hemlibra Indication, 1st Line Tecentriq Also on Agenda
November 16, 2018
- Chuikyo Agrees on October 2019 Drug Price Revision for Tax Hike, but Final Call Is Up to Govt
November 15, 2018
- MHLW Revises Imfinzi’s Optimal Use Guidelines for NSCLC, Calling for PD-L1 Expression Test
November 15, 2018
- Novo’s Ozempic Skips Listing for 3rd Time 8 Months after Approval
November 14, 2018
- Chuikyo OKs Listing of Astellas’ AML Med, Lilly’s Verzenio and More on Nov. 20
November 14, 2018
- Maviret Faces 25% Price Slash in Quarterly Review
November 14, 2018
- Despite Being 4th in ALK Class, Lorbrena Qualifies for PMP as It Gets 5% Pricing Premium
November 14, 2018
- New Health Minister Stresses Need for Drug Discovery Support at His 1st Confab with Industry
November 13, 2018
- Novartis’ SMA Gene Therapy Filed in Japan on Nov. 1 after US, EU; What Will Happen to Sakigake Status?
November 13, 2018
- MHLW Panel OKs Otsuka’s Alcohol Dependency Drug
November 12, 2018
- Panel Approves Health Ministry’s Proposal to Provide Package Insert Information in Electronic Form
November 12, 2018
- ViiV’s HIV Med Juluca Clears MHLW Panel for Quick Approval
November 12, 2018
- E19, M10 Guidelines Expected to Reach Step 2 at Upcoming ICH Meeting in US
November 9, 2018
- Nipro’s Sakigake-Designated Spinal Cord Injury Stem Cell Treatment Up for Approval Review on Nov. 21: MHLW
November 9, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…